Member Spotlight: Medicines Development for Global Health globalhealth.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalhealth.org Daily Mail and Mail on Sunday newspapers.
Abu Dhabi: An Abu Dhabi-led programme has treated a total of 117.9 million individuals across the world against polio and Neglected Tropical Diseases (NTDs).
Initiated by His Highness Sheikh Mohamed bin Zayed Al Nahyan, Abu Dhabi Crown Prince and Deputy Supreme Commander of the UAE Armed Forces, the Reaching the Last Mile (RLM) Initiative has also trained more than 715,000 health workers, and administered 523.5 million immunisations and medications, in an effort to end preventable diseases that affect the world’s poorest and most vulnerable communities.
All at risk
“The COVID-19 pandemic has underscored that if we can’t reach the most vulnerable, all of us are at risk. The last mile is about ensuring equity in access to quality health care for all, including the most difficult-to-reach and neglected populations. Inequality in global health is as serious as any disease. Without interventions that reach the most vulnerable, it will be impossible to eliminate deadly and debilit
Scientists and government pushing for ways to make mRNA vaccines here
Normal text size
Advertisement
The federal government is working with the biotech industry on ways to establish large-scale mRNA vaccine manufacturing in Australia as a group of senior scientists work on a parallel plan to enable local production of the cutting-edge jabs.
The mRNA coronavirus vaccines from Pfizer and Moderna yielded remarkably strong results in clinical trials and are expected to be much easier to reconfigured to cover new viral variants than more conventional inoculations such as AstraZeneca’s, which is being made in Australia by CSL.
Harry Al-Wassiti (L) and Colin Pouton are working on a COVID-19 vaccine at Monash University.
(2)
Novel approach for minimizing investment risks and stretching limited budgets has 375 innovations targeting infectious diseases under development
NEW YORK, Jan. 28, 2021 /PRNewswire/ The public-private initiatives that contributed to COVID-19 vaccine and drug development have showcased a model for accelerating biomedical innovation. However, the effectiveness of public-private partnerships in fighting global health threats had emerged long before this pandemic hit. Over the last decade, such alliances have produced a wide assortment of life-saving technologies targeting diseases that afflict billions in low-income countries, according to a new report from a group of 12 product development partnerships (PDPs) that assesses their impact and future potential.
Amgen Inc. has licensed one of its investigational pipeline drugs to Medicines Development for Global Health for the treatment of tuberculosis and leprosy.
Financial terms of the agreement were not disclosed. Medicines Development is a nonprofit biopharmaceutical company in Australia that will assume full responsibility for the further development and commercialization of AMG 634.
Thousand Oaks-based Amgen acquired the drug, called AMG 634, when it bought Otezla from Celgene in 2019 for $13.4 billion.
“Since tuberculosis and erythema nodosum leprosum remain challenging diseases in many countries around the world, Amgen sought an organization that could support the development of AMG 634 to address the global health unmet need,” Dr. David Reese, executive vice president of research and development at Amgen, said in a statement. “MDGH’s track record and experience in product development, global health, and neglected infectious diseases makes them an ideal company to furt